About Victoza®
Class: Brand liraglutide for T2D
Brand/Manufacturer: Novo Nordisk
Dosing: Daily subcutaneous (1.2-1.8 mg)
Mean weight loss: See LEADER
Pivotal trial: LEADER
Victoza® is Novo Nordisk's brand-name daily liraglutide approved for type 2 diabetes. LEADER trial established 13% reduction in major cardiovascular events. Retail $1,200/month. Now generic available since 2024.
Mechanism of action
Victoza® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is See LEADER body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Victoza®'s weight management indication is LEADER. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Victoza® via telehealth
Victoza® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Victoza® access — see the side panel for details.
FAQ
Is Victoza® FDA-approved?
The brand-name versions of Victoza® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Victoza® cost?
Brand-name Victoza® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.